

Bioblast Pharma Ltd.
Form 6-K
March 18, 2019

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: March 2019 (Report No. 2)

Commission file number: 001-36578

BIOBLAST PHARMA LTD.

(Translation of registrant's name into English)

PO Box 318, Tel-Aviv, Israel 6100201

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Edgar Filing: Bioblast Pharma Ltd. - Form 6-K

Form 20-F x Form 40-F "

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): _____

Results of the Meeting of Shareholders of the Company

At the Extraordinary General Meeting of Shareholders of the Registrant held on March 17, 2019 (the “**Meeting**”), the Registrant’s shareholders approved the agenda item as originally proposed. The agenda item that was approved is described further in Exhibits 99.1 and 99.2 to the Registrant’s Report on Form 6-K submitted to the Securities and Exchange Commission on February 19, 2019.

This Report of Foreign Private Issuer on Form 6-K of the Registrant is incorporated by reference into the registration statements on Form S-8 (File No. 333-203114 and 333-210459) of the Registrant, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bioblast Pharma Ltd.
(Registrant)

By: /s/ Dr. Dalia Megiddo
Name: Dr. Dalia Megiddo
Interim Chief Executive Officer

Date: March 18, 2019